#France #Vienna #Elitepharm #Freedom International Group #AI Nutraceuticals

Strategic Growth Through AI and Investment

In a bold move towards enhancing the nutraceutical sector, Freedom International Group (FIG) announced a significant investment in Elitepharm Laboratoires, adding itself as a leading shareholder in the French company. This strategic partnership aims to leverage artificial intelligence (AI) to refine dietary supplement formulations, marking a pivotal moment in FIG's expansion within the health and wellness industry.

Vision and Commitment

Narek Sirakanyan, FIG’s CEO, expressed optimism about the investment, stating it represents a crucial milestone in the organization's ongoing growth. With a solid management of assets exceeding €2.5 billion, FIG specializes in technology, finance, health, and wellness, making this venture a logical extension of their operational portfolio.

Elitepharm is recognized in France for its custom formulation and production of dietary supplements, providing solutions ranging from new product development to large-scale manufacturing. The company prides itself on having an adaptable and efficient manufacturing strategy that can cater to a variety of project requirements, regardless of their scale.

Enhancing Production through AI

The investment will facilitate the integration of FIG’s technological expertise, particularly from its IT division, Sessia. By incorporating sophisticated AI capabilities, Elitepharm aims to produce more effective products, achieving quicker and more reliable outcomes in research and development. This is particularly important in today’s rapidly evolving market where consumer demands continue to change.

Expansion Goals

The agreement between FIG and Elitepharm signifies a logical integration, as Project V, one of FIG’s initiatives, already produces 40 different products in collaboration with Elitepharm. The company aspires to elevate its status as a premier player in Europe, with a revenue target of €50 million by 2029. Currently, Elitepharm is producing roughly 25 million capsules a month with plans set to double this capacity.

This partnership stands on a mutual goal of industry innovation and operational excellence. Gérard Strauch, CEO of Elitepharm, has transformed the company into a recognized name in supplement production through scientific rigor and market foresight. By ensuring responsiveness to growing industry demands, Elitepharm focuses on quality, flexibility, and innovation.

Strategic Enhancements

With the backing of FIG, Elitepharm plans several strategic advancements:

• - Enhance Facilities: Upgrading existing facilities and acquiring new production sites to accommodate the increasing international demand.
• - Controlled Supply Chain: Acquiring farms that specialize in the cultivation of organic raw materials to improve traceability and quality control.
• - Broaden Private Label Portfolio: Expanding their offerings by collaborating with experts, enhancing their scientific teams, and pursuing horizontal acquisitions to remain competitive and ahead of market trends.

Sirakanyan emphasized that this acquisition is a key component of FIG's vertical integration strategy, with future plans for further acquisitions of farms that produce organic active ingredients sought after by Elitepharm.

Future Aspirations

Strauch enthusiastically stated, “This investment will accelerate our growth and establish Elitepharm as a key player in Europe. We share the same strategic vision and believe that innovation and industrialization are essential to our success.” The partnership reaffirms FIG and Elitepharm's commitment to building a robust, sustainable industrial model that promotes health and wellness across Europe.

This collaboration has the potential to transform the nutraceutical landscape, merging technology with health innovation to create superior products that respond effectively to consumer needs. As the industry evolves, the union of FIG's resources and Elitepharm's expertise may very well set new standards in supplement production and innovation.